
|Podcasts|December 14, 2022
The Cutaneous Connection: JAK Inhibitor Safety for Treating AD
Author(s)Kaitlyn Bader, Associate Editor
In this episode, Christopher Bunick, MD, PhD, discusses a paper he recently co-authored, which explores JAK inhibitor safety compared to traditional systemic therapies for atopic dermatitis.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
When Hives Do Not Quit: A Practical Update on Chronic Spontaneous Urticaria
2
KT-621 Produces 98% STAT6 Degradation in AD Patients
3
Site-Specific MED Variability Guides 308-nm Excimer Laser Dosing
4
Delgocitinib Offers Targeted Relief for the Painful Burden of Chronic Hand Eczema
5



















